NCT06731478 2026-03-16
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Daiichi Sankyo
Phase 3 Recruiting
Daiichi Sankyo
I-Mab Biopharma US Limited
Merus B.V.
Pfizer
Xijing Hospital